ALVR AlloVir Inc.

Biotech Analyst Ratings

Latest News

1. 05 May 2022 AlloVir Reports First Quarter 2022 Financial Results

   Initiated posoleucel registrational study to prevent six devastating viral infections and now enrolling high-risk allo-HCT patients in the U.S., Western Europe and Asia

   FDA granted RMAT designation to posoleucel for Phase 3 multi-virus prevention indication with an estimated annual addressable patient population of 40,000 allo-HCT patients

   Progressed enrollment in three Phase 3 studies for posoleucel and a Phase 2 trial for ALVR106

   Completed enrollment in Phase 2 study of posoleucel for the treatment of BK viremia in kidney transplant patients; initial blinded data will be presented at the American Transplant Congress in June

   AlloVir, Inc. (NASDAQ:ALVR), a multiple Phase 3 clinical trial stage allogeneic T cell immunotherapy company, today…

   View Full Article
2. 20 April 2022 FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

    Posoleucel's third RMAT designation marks an unprecedented regulatory distinction among cell and gene therapies

   Global Phase 3 multi-virus prevention trial initiated in March 2022 and is enrolling patients

   AlloVir (NASDAQ:ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead investigational multi-virus-specific T cell therapy, posoleucel, for the prevention of clinically significant infections and disease from six devastating viruses that commonly impact high-risk adult and pediatric patients following allogeneic hematopoietic cell transplant (allo-HCT) – adenovirus (AdV), BK virus…

   View Full Article
3. 31 March 2022 AlloVir Appoints Shawn Tomasello to Its Board of Directors

   AlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello brings more than 35 years of broad experience building and leading commercial organizations in the life sciences industry, with specific expertise in cell and gene therapy.

   "We're thrilled to welcome Shawn to our Board of Directors. Her depth of experience in building successful biopharmaceutical companies and leading innovative cell and gene therapies from clinical development to commercialization is invaluable to AlloVir, as we advance our multi-virus specific T cell platform and evolve into a commercial stage company," said Diana Brainard, M.D., Chief Executive…

   View Full Article
4. 22 March 2022 AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients

   Updated, preliminary Phase 2 data presented at EBMT Annual Meeting continue to demonstrate substantial reduction in the expected rate of clinically significant infections with posoleucel therapy

   21 of 24 patients were free of clinically significant infections through the Week 14 primary endpoint

   AlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the initiation of a Phase 3 registrational study of posoleucel, an allogeneic, off-the-shelf, multi-virus-specific T-cell (VST) therapy, for the prevention of clinically significant infections and end-organ diseases from six potentially life-threatening viruses – adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human…

   View Full Article
5. 11 February 2022 AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

   AlloVir (NASDAQ:ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:00 a.m. EST.

   A live webcast of the fireside chat will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. An archived replay will be available for approximately 30 days following the presentation.

   About AlloVir
   AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's…

   View Full Article